Skip to content
Tuesday 18 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,720.30
-0.28%
DAX
26,338.61
0.00%
CAC 40
8,579.60
0.00%
STOXX 50
6,530.45
0.00%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Wednesday 11 February 2015 11:32 am

Crowdfunding could transform healthcare through innovative disease diagnosis and new treatments

By: Sarah Spickernell

Add as a preferred source on Google

 
Crowdfunding provides a unique opportunity for the development of innovations that might otherwise fall by the wayside – between the government and private companies, there is simply not enough money available to turn all promising ideas into a reality.
 
The merits have already been shown across a range of industries – over the last few years, online funding through donations has brought an estimated £1.74bn to the UK's financial businesses alone.
 
But in healthcare, where digitisation has been slower than in most industries, crowdfunding could prove particularly transformational. Last year, the UK's National Information Board made a series of announcements emphasising how healthcare has found it more difficult to take advantage of digital technology than banking, travel or even the tax man. 
 
At the moment there are thousands of technologies and medications waiting for funding, which have the potential to make patient diagnosis and treatment faster and more effective. 
 
Not only that, but some currently unexplained disorders could be understood if enough money was provided for genome sequencing. The study of so-called “rare diseases”, which affect fewer than one in 200,000 people across the world, infrequently receives funding from the government.
 
Crowdfunding seems an ideal solution, and yesterday's news that researchers in Israel used it to identify the genetic cause of a young girl's disorder emphasises this.

Diagnosis through donations

By sequencing the genomes of the three-year-old and her direct family members, Dr Naom Shomron and his colleagues at Tel Aviv University found that a specific mutation in her DNA caused her top have involuntary eye movements, involuntary muscle contraction and progressive neurological decline. 
 
“By travelling through the complete human genome, we are able to locate, map, and analyze mutations involved in triggering certain rare diseases,” explained Shomron.
 
The technique he used, called whole exome sequencing (WES), costs around $1,500 (£985) per individual to complete, and since her her parents had to be sequenced as well, the price of the project came to $4,500 (£2,954).
 
Due to the high expense, Dr. Shomron had to raise the necessary funds from individual donors over the Internet, and in the end the Rare Genomics Institute proved to be a successful platform for this:
 
Crowdfunding provides the means for economically disadvantaged patients to pursue a genetic diagnosis for their ailment. Our project reached its financial goal of $5,000 within 50 days. We were pleased, to say the least. Crowdfunding is a simple and efficient solution for families with rare genetic diseases who lack private or outside funding sources.

Dedicated to healthcare

In order to help people like Shomron carry out their projects, a number of crowdfunding sites dedicated exclusively to healthcare have been set up. Among them is TheBioCrowd, which aims to make it easier for small and early stage healthcare companies to bring a treatment to market. 
 
Udy Onwudike, chief executive of the site, says he set it up because the world of healthcare investment is “so competitive”:
 
“Investors are bombarded with offers and many great companies with fantastic business plans, great teams and a strong clinical product get lost in the crowd,” he writes on the site. 
 
Due to the fact that until a treatment has been deemed to be clinically safe it cannot be administered to patients, the key problem that these companies face is that they have limited sources of incoming revenue until they have a treatment approved and selling on the open market, something that we are aiming to change.
 
Other sites set up just for medical crowdfunding include MedStartr and HealthTechHatch. Many of them are already doing very well – an average project on MedStartr's website raises more than $13,000 immediately and more than $405,000 (£266,000) in the following six months, according to Information Week.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Jobs and Money

Categories

  • Money

Related Topics

  • Alternative finance
  • Crowdfunding

Trending Articles

  • As it happened: FTSE 100 drops as oil prices rise after Trump makes Hormuz threat

  • US bond market jitters spark UK economy recession warning

  • Aldi boss wades into supermarket ‘price-gouging’ row

  • Monzo chair makes early exit after boardroom rift

  • New Premier League rules could see £11bn invested into new stadiums

More from Morning Wire

  • London-listed healthcare services firm hit by cyberattack

    Markets
    Assura has been the subject of a ferocious bidding war for nearly six months
  • Jobs market ‘stops moving’ as employment costs weigh on hirers

    Economics
    The recruitment industry is grappling with a slowdown in hiring among UK employers and wider macro-economic uncertainty.
  • Real Chemistry Launches Real Chemistry ANATOMI, an AI Ecosystem Purpose-Built for Healthcare Commercialization

    Business Wire
  • Monzo founder joins Anthropic as AI talent race heats up

    Tech
    Claude AI interface showcasing advanced features in a business setting
  • Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026

    Business Wire
  • Curaleaf Launches Free CPD-Accredited Platform to Close Medical Cannabis Training Gap for UK Healthcare Professionals

    Business Wire
  • InterSystems Recognized as a Leader in the Gartner® Magic Quadrant™ for Enterprise Electronic Health Records

    Business Wire
  • NADclinic and GCLS Announce Strategic Collaboration in Longevity and Performance Medicine Education

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook